Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.

× No keyword cloud information.

11 in total

1. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.

Authors: Eisaku Iwanaga; Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
Journal: Haematologica Date: 2009-01-30 Impact factor: 9.941

Review 2. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors: Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal: Leuk Lymphoma Date: 2014-02-17

3. Myelofibrosis 2012: it's complicated.

Authors: Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal: Ther Adv Hematol Date: 2012-06

4. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.

Authors: Montserrat Estruch; Kristian Reckzeh; Camilla Vittori; Anders Centio; Mina Ali; Sophia Engelhard; Ling Zhao; Kyoung Jae Won; Paul Liu; Bo Torben Porse; Kim Theilgaard-Mönch
Journal: Leukemia Date: 2020-12-09 Impact factor: 11.528

5. Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree.

Authors: Kiran Tawana; Jun Wang; Péter A Király; Krisztián Kállay; Gábor Benyó; Marianna Zombori; Judit Csomor; Ahad Al Seraihi; Ana Rio-Machin; András Matolcsy; Claude Chelala; Jamie Cavenagh; Jude Fitzgibbon; Csaba Bödör
Journal: Eur J Hum Genet Date: 2017-05-17 Impact factor: 4.246

Review 6. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors: Ehab Atallah; Srdan Verstovsek
Journal: Expert Rev Anticancer Ther Date: 2009-05 Impact factor: 4.512

Review 7. Therapy-related myeloid leukemia.

Authors: Lucy A Godley; Richard A Larson
Journal: Semin Oncol Date: 2008-08 Impact factor: 4.929

Review 8. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.

Authors: Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Clara D Bloomfield
Journal: Curr Opin Oncol Date: 2008-11 Impact factor: 3.645

9. JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

Authors: M-C Lo; L F Peterson; M Yan; X Cong; J H Hickman; R C Dekelver; D Niewerth; D-E Zhang
Journal: Leukemia Date: 2013-07-01 Impact factor: 11.528

10. Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.

Authors: Steven Wang; Jie Yan; Guangde Zhou; Rebecca Heintzelman; J Steve Hou
Journal: Case Rep Hematol Date: 2016-09-26